董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Benad Goldwasser | 男 | Chairman of the Board and Director | 75 | 25.00万美元 | 71.55 | 2026-03-19 |
| Jackson Schneider | 男 | Director | 61 | 26.60万美元 | 2.08 | 2026-03-19 |
| Inbal Kreiss | 女 | Director | 59 | 3.20万美元 | 3.10 | 2026-03-19 |
| Carlo Papa | 男 | Director | 54 | 26.20万美元 | 未持股 | 2026-03-19 |
| Ronit Rubin | 女 | Director | 61 | 2.40万美元 | 1.25 | 2026-03-19 |
| Moshe Arkin | 男 | Director | 73 | 1.60万美元 | 792.38 | 2026-03-19 |
| Zeev Vurembrand | 男 | Director | 74 | 3.20万美元 | 4.60 | 2026-03-19 |
| Nir Nimrodi | 男 | Director | 57 | 2.90万美元 | 1.50 | 2026-03-19 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Yehu Ofer | 男 | Chief Executive Officer | 60 | 141.60万美元 | 31.93 | 2026-03-19 |
| Einav Brenner | 女 | Chief Financial Officer | 44 | 40.30万美元 | 未持股 | 2026-03-19 |
| Eilam Sagi | 男 | Chief Business Officer | 51 | 未披露 | 未持股 | 2026-03-19 |
董事简历
中英对照 | 中文 | 英文- Benad Goldwasser
-
Benad Goldwasser曾担任Odysight.Ai Inc.董事长。自2019年12月起担任Ai Inc.的董事会成员，并担任Odysight.Ai Inc.的董事长。自成立以来，他一直担任ai Ltd.的董事会成员。Goldwasser教授是一位连续创业者和退休的泌尿外科医生。2016年，Goldwasser教授与上海政府投资公司SAIL共同创立了一家风险投资基金。Goldwasser教授自2017年起担任Innoventric Ltd.董事会成员，自2021年1月起担任Inspira Technologies Ltd.董事会成员。2013年至2016年，他担任BioCanCell Ltd. （TASE： BICL）的外部董事。Goldwasser教授是Vidamed Inc.、Medinol Ltd.、Rita Medical Inc.、Optonol Ltd.和GI View Ltd.的联合创始人。他曾担任以色列风险投资公司Biomedical Investments Ltd.的董事总经理。在他的医疗生涯中，他曾担任the Chaim Sheba medical Center泌尿科主席和Tel-Aviv University外科教授。Goldwasser教授拥有特拉维夫大学的医学博士和工商管理硕士学位。
Benad Goldwasser has served as chairman of board of directors since December 2019, and has served as chairman of Odysight.ai Ltd.'s board of directors since its inception. Prof. Goldwasser is a serial entrepreneur and retired urology medical doctor. In 2016, Prof. Goldwasser helped launch a venture capital fund together with SAIL, a Shanghai Government investment company. Prof. Goldwasser has served as a member of the board of directors of Innoventric Ltd. since 2017. From January 2021 to January 2025, Prof. Goldwasser served as Chairman of the Board of Directors of Inspira Technologies Ltd (Nasdaq: IINN). From 2013 2016 Prof. Goldwasser served as an external director of BioCanCell Ltd. (TASE: BICL). Prof. Goldwasser was the co founder of Vidamed Inc., Medinol Ltd., Rita Medical Inc., Optonol Ltd. and GI View Ltd. Prof. Goldwasser served as managing director of Biomedical Investments Ltd., an Israeli Venture Capital firm. During his medical career, he served as Chairman of Urology at the Chaim Sheba Medical Center and Professor of Surgery at Tel Aviv University. Prof. Goldwasser holds MD and MBA degrees from Tel Aviv University. - Benad Goldwasser曾担任Odysight.Ai Inc.董事长。自2019年12月起担任Ai Inc.的董事会成员，并担任Odysight.Ai Inc.的董事长。自成立以来，他一直担任ai Ltd.的董事会成员。Goldwasser教授是一位连续创业者和退休的泌尿外科医生。2016年，Goldwasser教授与上海政府投资公司SAIL共同创立了一家风险投资基金。Goldwasser教授自2017年起担任Innoventric Ltd.董事会成员，自2021年1月起担任Inspira Technologies Ltd.董事会成员。2013年至2016年，他担任BioCanCell Ltd. （TASE： BICL）的外部董事。Goldwasser教授是Vidamed Inc.、Medinol Ltd.、Rita Medical Inc.、Optonol Ltd.和GI View Ltd.的联合创始人。他曾担任以色列风险投资公司Biomedical Investments Ltd.的董事总经理。在他的医疗生涯中，他曾担任the Chaim Sheba medical Center泌尿科主席和Tel-Aviv University外科教授。Goldwasser教授拥有特拉维夫大学的医学博士和工商管理硕士学位。
- Benad Goldwasser has served as chairman of board of directors since December 2019, and has served as chairman of Odysight.ai Ltd.'s board of directors since its inception. Prof. Goldwasser is a serial entrepreneur and retired urology medical doctor. In 2016, Prof. Goldwasser helped launch a venture capital fund together with SAIL, a Shanghai Government investment company. Prof. Goldwasser has served as a member of the board of directors of Innoventric Ltd. since 2017. From January 2021 to January 2025, Prof. Goldwasser served as Chairman of the Board of Directors of Inspira Technologies Ltd (Nasdaq: IINN). From 2013 2016 Prof. Goldwasser served as an external director of BioCanCell Ltd. (TASE: BICL). Prof. Goldwasser was the co founder of Vidamed Inc., Medinol Ltd., Rita Medical Inc., Optonol Ltd. and GI View Ltd. Prof. Goldwasser served as managing director of Biomedical Investments Ltd., an Israeli Venture Capital firm. During his medical career, he served as Chairman of Urology at the Chaim Sheba Medical Center and Professor of Surgery at Tel Aviv University. Prof. Goldwasser holds MD and MBA degrees from Tel Aviv University.
- Jackson Schneider
-
Jackson Schneider，自2023年12月起担任我们的董事会成员。施耐德先生目前是纽约哥伦比亚大学的兼职高级教授。2014年1月至2022年11月，Schneider先生担任拉丁美洲领先的航空航天和国防公司Embraer Defense & Security的总裁兼首席执行官，并于2020年8月至2022年8月担任伦敦国王学院战争研究系的访问高级研究员（非常驻）。在此之前，施耐德先生曾在巴西航空工业公司担任其他职务，并在梅赛德斯-奔驰Do Brasil LTDA、戴姆勒-克莱斯勒（梅赛德斯-奔驰）和联合利华 Do Brasil担任一系列高级管理职务。施耐德先生还在Tempest S.A.、Visiona Tecnologia Aerospacial S.A.和葡萄牙航空航天工业公司OGMA的董事会任职，这三家公司均隶属于巴西航空工业公司，任期至2023年4月。他目前在Sonda Tecnologias（巴西）、Abra Aviation Group（伦敦）、CBMM（巴西）和Mercedes-Benz Do Brasil的顾问委员会或董事会任职。此外，施耐德先生曾在多个行业协会担任领导职务，目前担任圣保罗州工业联合会最高贸易和商业委员会主席。他拥有1982-1986年UFRGS/UNB的法律学位以及与加拿大多伦多罗特曼学院合作的巴西圣保罗商学院的MBA学位。
Jackson Schneider Jackson Medeiros de Farias Schneider has served on board of directors since December 2023. Mr. Schneider is currently an Adjunct Professor Senior at Columbia University in New York. From January 2014 to November 2022, Mr. Schneider served as President and CEO of Embraer Defense & Security, a leading Latin American aerospace and defense company and, from August 2020 to August 2022, he served as a visiting senior research fellow (non resident) in the Department of War Studies at King's College in London. Before this, Mr. Schneider served in other capacities for Embraer and in a series of senior management positions for Mercedes Benz Do Brasil LTDA, Daimler Chrysler (Mercedes Benz), and Unilever do Brasil. Mr. Schneider also served on the board of directors of Tempest S.A., Visiona Tecnologia Aerospacial S.A., and OGMA, the Portugal Aerospace industry, each affiliated with Embraer, until April 2023 and on the board of directors of Mercedes Benz Do Brasil until December 2025. He currently serves on the advisory board or board of directors of Sonda Tecnologias (Brazil), Abra Aviation Group (London), CBMM (Brazil) and Casas Bahia (Brazil). In addition, Mr. Schneider has served in leadership roles in vario industry associations, including as the President of the Superior Council for Trade and Commerce in the Federation of Indtries of the State of Sao Paulo until December 2025. He holds a law degree from 1982 to 1986 from UFRGS/UNB and an MBA from the Biness School Sao Paulo in Brazil in partnership with the Rotman School in Toronto, Canada. - Jackson Schneider，自2023年12月起担任我们的董事会成员。施耐德先生目前是纽约哥伦比亚大学的兼职高级教授。2014年1月至2022年11月，Schneider先生担任拉丁美洲领先的航空航天和国防公司Embraer Defense & Security的总裁兼首席执行官，并于2020年8月至2022年8月担任伦敦国王学院战争研究系的访问高级研究员（非常驻）。在此之前，施耐德先生曾在巴西航空工业公司担任其他职务，并在梅赛德斯-奔驰Do Brasil LTDA、戴姆勒-克莱斯勒（梅赛德斯-奔驰）和联合利华 Do Brasil担任一系列高级管理职务。施耐德先生还在Tempest S.A.、Visiona Tecnologia Aerospacial S.A.和葡萄牙航空航天工业公司OGMA的董事会任职，这三家公司均隶属于巴西航空工业公司，任期至2023年4月。他目前在Sonda Tecnologias（巴西）、Abra Aviation Group（伦敦）、CBMM（巴西）和Mercedes-Benz Do Brasil的顾问委员会或董事会任职。此外，施耐德先生曾在多个行业协会担任领导职务，目前担任圣保罗州工业联合会最高贸易和商业委员会主席。他拥有1982-1986年UFRGS/UNB的法律学位以及与加拿大多伦多罗特曼学院合作的巴西圣保罗商学院的MBA学位。
- Jackson Schneider Jackson Medeiros de Farias Schneider has served on board of directors since December 2023. Mr. Schneider is currently an Adjunct Professor Senior at Columbia University in New York. From January 2014 to November 2022, Mr. Schneider served as President and CEO of Embraer Defense & Security, a leading Latin American aerospace and defense company and, from August 2020 to August 2022, he served as a visiting senior research fellow (non resident) in the Department of War Studies at King's College in London. Before this, Mr. Schneider served in other capacities for Embraer and in a series of senior management positions for Mercedes Benz Do Brasil LTDA, Daimler Chrysler (Mercedes Benz), and Unilever do Brasil. Mr. Schneider also served on the board of directors of Tempest S.A., Visiona Tecnologia Aerospacial S.A., and OGMA, the Portugal Aerospace industry, each affiliated with Embraer, until April 2023 and on the board of directors of Mercedes Benz Do Brasil until December 2025. He currently serves on the advisory board or board of directors of Sonda Tecnologias (Brazil), Abra Aviation Group (London), CBMM (Brazil) and Casas Bahia (Brazil). In addition, Mr. Schneider has served in leadership roles in vario industry associations, including as the President of the Superior Council for Trade and Commerce in the Federation of Indtries of the State of Sao Paulo until December 2025. He holds a law degree from 1982 to 1986 from UFRGS/UNB and an MBA from the Biness School Sao Paulo in Brazil in partnership with the Rotman School in Toronto, Canada.
- Inbal Kreiss
-
Inbal Kreiss，自2021年4月起担任我们的董事会成员。Kreiss女士目前是IAI系统、导弹和空间司的创新部主管，她自2020年4月起担任该职位，并自2021年4月起担任国际空间站科学和技术任务RAKIA的主席。自2013年以来，Kreiss女士担任IAI空间司副司长，领导为以色列和外国用户开发、建造、发射和运营观测和通信卫星。在此之前，Kreiss女士曾在IAI内担任多个领导职务，包括2000年至2006年担任以色列Arrow 2反弹道导弹防御系统总工程师，2007年至2013年担任Arrow 3大气层外拦截器项目经理。Kreiss女士拥有以色列理工学院Technion化学工程学士学位、特拉维夫大学高级管理人员工商管理硕士学位，并在麻省理工学院航空航天系完成了访问研究奖学金。
Inbal Kreiss Inbal Kreiss has served on board of directors since April 2021. Ms. Kreiss is currently the Chief of Innovation at the Systems, Missiles and Space Division of the IAI, a position she has held since April 2020, and Chairwoman of RAKIA, Scientific and Technological Mission to the International Space Station, a position she has held since April 2021. Since 2013, Ms. Kreiss has served as Deputy Director of the Space Division at IAI, leading the development, construction, launch and operation of observation and communication satellites. Ms. Kreiss has served as a member of the board of directors and audit committee of Phoenix Financial Ltd (TLV:PHOE) since January 2025. Prior to that, Ms. Kreiss held vario leadership positions within IAI, including chief engineer of Israel's Arrow 2 anti ballistic missile defense system from 2000 to 2006, and project manager of the Arrow 3 exo atmospheric interceptor from 2007 to 2013. Ms. Kreiss holds a B.Sc degree in chemical engineering from the Technion, Israeli Institute of Technology, an Executive Masters in Biness Administration degree from Tel Aviv University, and completed a visiting research fellowship at the Aeronautics & Astronautics Department of the Massachetts Institute of Technology. - Inbal Kreiss，自2021年4月起担任我们的董事会成员。Kreiss女士目前是IAI系统、导弹和空间司的创新部主管，她自2020年4月起担任该职位，并自2021年4月起担任国际空间站科学和技术任务RAKIA的主席。自2013年以来，Kreiss女士担任IAI空间司副司长，领导为以色列和外国用户开发、建造、发射和运营观测和通信卫星。在此之前，Kreiss女士曾在IAI内担任多个领导职务，包括2000年至2006年担任以色列Arrow 2反弹道导弹防御系统总工程师，2007年至2013年担任Arrow 3大气层外拦截器项目经理。Kreiss女士拥有以色列理工学院Technion化学工程学士学位、特拉维夫大学高级管理人员工商管理硕士学位，并在麻省理工学院航空航天系完成了访问研究奖学金。
- Inbal Kreiss Inbal Kreiss has served on board of directors since April 2021. Ms. Kreiss is currently the Chief of Innovation at the Systems, Missiles and Space Division of the IAI, a position she has held since April 2020, and Chairwoman of RAKIA, Scientific and Technological Mission to the International Space Station, a position she has held since April 2021. Since 2013, Ms. Kreiss has served as Deputy Director of the Space Division at IAI, leading the development, construction, launch and operation of observation and communication satellites. Ms. Kreiss has served as a member of the board of directors and audit committee of Phoenix Financial Ltd (TLV:PHOE) since January 2025. Prior to that, Ms. Kreiss held vario leadership positions within IAI, including chief engineer of Israel's Arrow 2 anti ballistic missile defense system from 2000 to 2006, and project manager of the Arrow 3 exo atmospheric interceptor from 2007 to 2013. Ms. Kreiss holds a B.Sc degree in chemical engineering from the Technion, Israeli Institute of Technology, an Executive Masters in Biness Administration degree from Tel Aviv University, and completed a visiting research fellowship at the Aeronautics & Astronautics Department of the Massachetts Institute of Technology.
- Carlo Papa
-
Carlo Pappa，自2024年9月起担任我们的董事会成员。Papa博士自2024年8月起担任哥伦比亚大学哥伦比亚可持续投资中心高级研究员，并自2023年6月起担任意大利出口信贷机构SACE的影响咨询委员会成员。2015年4月至2024年6月，Papa博士担任意大利智库Enel基金会的董事总经理，并担任Enel集团与学术和研究机构关系的全球主管。Papa博士此前曾在Enel Green Power担任首席创新官，并曾在Enel集团担任多个职位，包括董事长办公室的参谋长、俄罗斯和乌克兰业务发展主管（发电部门）以及Enel Capital Corporate Venture Fund的联合创始人和投资经理。帕帕博士目前担任意大利可持续发展和气候变化国家博士、联合国能源转型理事会工程师和Harambee Africa的董事会、顾问委员会或执行委员会成员。Papa博士在意大利巴勒莫大学获得经济学学士学位-管理和金融理学硕士学位，在伦敦经济学院、Stern NYU、巴黎高等商学院获得EMBA Trium全球执行官，在罗马Tor Vergata大学获得管理工程博士学位。
Carlo Papa Dr. Carlo Papa has served on board of directors since September 2024 and as Chairman of Odysight.ai EU since January 2025. Dr. Papa is currently Senior Fellow at the Columbia Center on Stainable Investment at Columbia University since Augt 2024. From January 2025 to December 2025, Dr. Papa served as Chief Economics Advisor at Berkeley Research Group; from June 2023 to June 2025, as a member of the Impact Advisory Board of SACE, Italy's export credit agency; and from April 2015 to June 2024, as Managing Director of the Enel Foundation 4, an Italian think tank, and as Global Head of Relationships with academic and research institutions for Enel Group. Dr. Papa previoly served as Chief Innovation Officer at Enel Green Por and has held several positions with the Enel Group, including Chief of Staff of the Chairman's Office, Head of Biness Development for Rsia and Ukraine (Por Generation Division) and co founder of and Investment Manager for Enel Capital Corporate Venture Fund. Dr. Papa currently serves on the board, advisory board or executive committee of Italy's National PhD in Stainable Development and Climate Change, the UN's Council Engineers for Energy Transition and Harambee Africa. Dr. Papa received a BSc in Economics MSc in Management and Finance from Palermo University in Italy, an EMBA Trium Global Executive from London School of Economics, Stern NYU, HEC Paris and a PhD in Management Engineering from Tor Vergata University in Rome. - Carlo Pappa，自2024年9月起担任我们的董事会成员。Papa博士自2024年8月起担任哥伦比亚大学哥伦比亚可持续投资中心高级研究员，并自2023年6月起担任意大利出口信贷机构SACE的影响咨询委员会成员。2015年4月至2024年6月，Papa博士担任意大利智库Enel基金会的董事总经理，并担任Enel集团与学术和研究机构关系的全球主管。Papa博士此前曾在Enel Green Power担任首席创新官，并曾在Enel集团担任多个职位，包括董事长办公室的参谋长、俄罗斯和乌克兰业务发展主管（发电部门）以及Enel Capital Corporate Venture Fund的联合创始人和投资经理。帕帕博士目前担任意大利可持续发展和气候变化国家博士、联合国能源转型理事会工程师和Harambee Africa的董事会、顾问委员会或执行委员会成员。Papa博士在意大利巴勒莫大学获得经济学学士学位-管理和金融理学硕士学位，在伦敦经济学院、Stern NYU、巴黎高等商学院获得EMBA Trium全球执行官，在罗马Tor Vergata大学获得管理工程博士学位。
- Carlo Papa Dr. Carlo Papa has served on board of directors since September 2024 and as Chairman of Odysight.ai EU since January 2025. Dr. Papa is currently Senior Fellow at the Columbia Center on Stainable Investment at Columbia University since Augt 2024. From January 2025 to December 2025, Dr. Papa served as Chief Economics Advisor at Berkeley Research Group; from June 2023 to June 2025, as a member of the Impact Advisory Board of SACE, Italy's export credit agency; and from April 2015 to June 2024, as Managing Director of the Enel Foundation 4, an Italian think tank, and as Global Head of Relationships with academic and research institutions for Enel Group. Dr. Papa previoly served as Chief Innovation Officer at Enel Green Por and has held several positions with the Enel Group, including Chief of Staff of the Chairman's Office, Head of Biness Development for Rsia and Ukraine (Por Generation Division) and co founder of and Investment Manager for Enel Capital Corporate Venture Fund. Dr. Papa currently serves on the board, advisory board or executive committee of Italy's National PhD in Stainable Development and Climate Change, the UN's Council Engineers for Energy Transition and Harambee Africa. Dr. Papa received a BSc in Economics MSc in Management and Finance from Palermo University in Italy, an EMBA Trium Global Executive from London School of Economics, Stern NYU, HEC Paris and a PhD in Management Engineering from Tor Vergata University in Rome.
- Ronit Rubin
-
Ronit Rubin，曾在Odysight.Ai Inc.服役。自2023年12月起担任Ai Inc.的董事会成员。她目前担任AllCloud的EMEA总裁，AllCloud是一家专业服务公司，为组织提供云启用和转型工具，自2016年以来一直担任该职位。在此之前，她曾担任Partner Communications Ltd.的业务部副总裁和信息技术副总裁，以及Cal-Israel Credit Cards Ltd.的信息技术副总裁。从1984年到2006年，她曾担任以色列国防军海军的各种职务，包括计算机部门的指挥官和信息系统部门的负责人。她目前担任CardCom Technology的董事会成员。她持有以色列Ramat Gan Bar-Ilan大学的经济学和物流学士学位，以及以色列beersheva的Ben-Gurion大学的商业管理硕士学位。
Ronit Rubin Ronit Rubin has served on board of directors since December 2023. Ms. Rubin is currently EMEA President for AllCloud, a professional services company providing organizations with the tools for cloud enablement and transformation, a position she has held since 2016. Prior to this, Ms. Rubin served as VP, Biness Division and VP, Information Technology at Partner Communications Ltd. and as VP, Information Technology at Cal Israel Credit Cards Ltd. From 1984 2006, Ms. Rubin served in vario roles for the navy of the Israeli Defense Forces, including as Commander, Computers Unit and Head of Information Systems Department. She currently serves as a board member of CardCom Technology. Ms. Rubin holds a BA in Economics & Logistics from Bar Ilan University in Ramat Gan, Israel, and an MA in Biness Management from Ben Gurion University of the Negev in Be'er Sheva, Israel. - Ronit Rubin，曾在Odysight.Ai Inc.服役。自2023年12月起担任Ai Inc.的董事会成员。她目前担任AllCloud的EMEA总裁，AllCloud是一家专业服务公司，为组织提供云启用和转型工具，自2016年以来一直担任该职位。在此之前，她曾担任Partner Communications Ltd.的业务部副总裁和信息技术副总裁，以及Cal-Israel Credit Cards Ltd.的信息技术副总裁。从1984年到2006年，她曾担任以色列国防军海军的各种职务，包括计算机部门的指挥官和信息系统部门的负责人。她目前担任CardCom Technology的董事会成员。她持有以色列Ramat Gan Bar-Ilan大学的经济学和物流学士学位，以及以色列beersheva的Ben-Gurion大学的商业管理硕士学位。
- Ronit Rubin Ronit Rubin has served on board of directors since December 2023. Ms. Rubin is currently EMEA President for AllCloud, a professional services company providing organizations with the tools for cloud enablement and transformation, a position she has held since 2016. Prior to this, Ms. Rubin served as VP, Biness Division and VP, Information Technology at Partner Communications Ltd. and as VP, Information Technology at Cal Israel Credit Cards Ltd. From 1984 2006, Ms. Rubin served in vario roles for the navy of the Israeli Defense Forces, including as Commander, Computers Unit and Head of Information Systems Department. She currently serves as a board member of CardCom Technology. Ms. Rubin holds a BA in Economics & Logistics from Bar Ilan University in Ramat Gan, Israel, and an MA in Biness Management from Ben Gurion University of the Negev in Be'er Sheva, Israel.
- Moshe Arkin
-
Moshe Arkin自2014年以来一直担任我们的董事会主席。Moshe Arkin目前是几家私人制药和医疗设备公司的董事，其中包括Exalenz Bioscience Ltd.，该公司自2006年以来一直是胃肠和肝脏疾病先进系统的开发商，Sonivie Ltd.是一家开发肺动脉高压治疗系统的公司，Digma Medical，一家开发治疗2型糖尿病和其他代谢综合征疾病中存在的胰岛素抵抗的系统的公司，以及一家开发心脏瓣膜设备的公司ValCare Medical。从2005年到2008年，Moshe Arkin先生担任Perrigo Company的仿制药主管，并从2005年到2011年担任其董事会副主席。在加入我们之前，Moshe Arkin先生曾担任CCAM Biotherapeutics Ltd.的董事，该公司从2012年到2015年被默克制药公司收购，专注于发现和开发治疗癌症的新型免疫疗法从1972年Agis Industries Ltd.成立到2005年被Perrigo Company收购，Moshe Arkin先生一直担任其董事长。Moshe Arkin先生拥有以色列特拉维夫大学心理学学士学位。
Moshe Arkin has served as interim chief executive officer since January 1, 2025 and has served as chairman of board of directors since 2014. In May 2022, Mr. Moshe Arkin's role was expanded to Executive Chairman to reflect Mr. Arkin's expanded role at the Company. Mr. Moshe Arkin currently sits on the board of directors of several private pharmaceutical and medical device companies including SoniVie Ltd., a company developing systems for the treatment of pulmonary arterial hypertension, Digma Medical, a company developing systems to treat insulin resistance present in type 2 diabetes and other metabolic syndrome diseases, and Valcare Medical, a company developing heart valve devices. From 2005 to 2008, Mr. Moshe Arkin served as the head of generics at Perrigo Company and from 2005 until 2011 as the vice chairman of its board of directors. Prior to joining , Mr. Moshe Arkin served as a director of cCAM Biotherapeutics Ltd., a company foced on the discovery and development of novel immunotherapies to treat cancer from 2012 until its acquisition in 2015 by Merck & Co., Inc. Mr. Moshe Arkin served as chairman of Agis Indtries Ltd. from its inception in 1972 until its acquisition by Perrigo Company in 2005. Mr. Moshe Arkin holds a B.A. in psychology from the Tel Aviv University, Israel. - Moshe Arkin自2014年以来一直担任我们的董事会主席。Moshe Arkin目前是几家私人制药和医疗设备公司的董事，其中包括Exalenz Bioscience Ltd.，该公司自2006年以来一直是胃肠和肝脏疾病先进系统的开发商，Sonivie Ltd.是一家开发肺动脉高压治疗系统的公司，Digma Medical，一家开发治疗2型糖尿病和其他代谢综合征疾病中存在的胰岛素抵抗的系统的公司，以及一家开发心脏瓣膜设备的公司ValCare Medical。从2005年到2008年，Moshe Arkin先生担任Perrigo Company的仿制药主管，并从2005年到2011年担任其董事会副主席。在加入我们之前，Moshe Arkin先生曾担任CCAM Biotherapeutics Ltd.的董事，该公司从2012年到2015年被默克制药公司收购，专注于发现和开发治疗癌症的新型免疫疗法从1972年Agis Industries Ltd.成立到2005年被Perrigo Company收购，Moshe Arkin先生一直担任其董事长。Moshe Arkin先生拥有以色列特拉维夫大学心理学学士学位。
- Moshe Arkin has served as interim chief executive officer since January 1, 2025 and has served as chairman of board of directors since 2014. In May 2022, Mr. Moshe Arkin's role was expanded to Executive Chairman to reflect Mr. Arkin's expanded role at the Company. Mr. Moshe Arkin currently sits on the board of directors of several private pharmaceutical and medical device companies including SoniVie Ltd., a company developing systems for the treatment of pulmonary arterial hypertension, Digma Medical, a company developing systems to treat insulin resistance present in type 2 diabetes and other metabolic syndrome diseases, and Valcare Medical, a company developing heart valve devices. From 2005 to 2008, Mr. Moshe Arkin served as the head of generics at Perrigo Company and from 2005 until 2011 as the vice chairman of its board of directors. Prior to joining , Mr. Moshe Arkin served as a director of cCAM Biotherapeutics Ltd., a company foced on the discovery and development of novel immunotherapies to treat cancer from 2012 until its acquisition in 2015 by Merck & Co., Inc. Mr. Moshe Arkin served as chairman of Agis Indtries Ltd. from its inception in 1972 until its acquisition by Perrigo Company in 2005. Mr. Moshe Arkin holds a B.A. in psychology from the Tel Aviv University, Israel.
- Zeev Vurembrand
-
Zeev Vurembrand，曾在Odysight.Ai Inc.服役。自2021年5月起担任Ai Inc.的董事。Vurembrand先生目前是Vurembrand Management & Innovation Ltd.的首席执行官兼所有者，他自2019年3月以来一直担任该职位，并自2017年以来一直是Bezeq the israel Telecommunication Corp. Ltd. （TASE： BEZQ）的董事会成员。从2019年到2023年12月，他还担任Lageen Ltd.的董事会主席。从2013年到2019年，他担任以色列第三大医疗保健组织Kupat Holim Meuhedet的首席执行官。从2008年到2013年，他担任Alon Holding Blue Square - Israel Ltd.的首席执行官。在此之前，从2007年到2008年，他担任Phoenix Investments and Finance Ltd.的首席执行官。从2002年到2007年，他是Clalit Health Services Group（以色列最大的医疗保健组织）的首席执行官。他曾担任多个董事会成员，包括2014年至2016年非洲以色列住宅有限公司（TASE： AFRE）， 2006年至2007年贴现银行（TASE：DSCT）， 2005年至2006年U-Bank， 2001年至2006年蓝色广场以色列（TASE： BSI）和Dikla医疗保险有限公司（1995年至2002年）。自2019年以来，他还担任Bar Ilan University的董事会成员。他持有以色列理工学院（Technion, israel Institute of Technology）工业工程和管理学士学位。
Zeev Vurembrand Zeev Vurembrand has served on board of directors since May 2021. Mr. Vurembrand is currently the Chief Executive Officer and Owner of Vurembrand Management & Innovation Ltd., a position he has held since March 2019, and has been a member of the board of Bezeq the Israeli Telecommunication Corp. Ltd. (TASE: BEZQ) since 2017 and director of Isras Investment Company Ltd. (TASE: ISRAS) since January 2025. Mr. Vurembrand also served as chairman of the board of Lageen Ltd. from 2019 until December 2023. From 2013 until 2019, Mr. Vurembrand was the Chief Executive Officer of Kupat Holim Meuhedet, Israel's third largest health care organization. From 2008 until 2013, he was the Chief Executive Officer of Alon Holding Blue Square – Israel Ltd., and prior to that, from 2007 until 2008, he was the Chief Executive Officer of Phoenix Investments and Finance Ltd. Earlier in his career, from 2002 until 2007, Mr. Vurembrand was the Chief Executive Officer of Clalit Health Services Group, Israel's largest health care organization. Mr. Vurembrand has served on numero boards of directors, including Africa Israel Residences LTD. (TASE: AFRE) from 2014 until 2016, Discount Bank (TASE:DSCT) 2006 until 2007, U Bank from 2005 until 2006, Blue Square Israel (TASE: BSI) from 2001 until 2006, and Dikla Medical Insurance Ltd. from 1995 until 2002. Mr. Vurembrand has also served on the board of trtees of Bar Ilan University since 2019. Mr. Vurembrand holds a B.Sc degree in indtrial engineering and management from the Technion, Israeli Institute of Technology. - Zeev Vurembrand，曾在Odysight.Ai Inc.服役。自2021年5月起担任Ai Inc.的董事。Vurembrand先生目前是Vurembrand Management & Innovation Ltd.的首席执行官兼所有者，他自2019年3月以来一直担任该职位，并自2017年以来一直是Bezeq the israel Telecommunication Corp. Ltd. （TASE： BEZQ）的董事会成员。从2019年到2023年12月，他还担任Lageen Ltd.的董事会主席。从2013年到2019年，他担任以色列第三大医疗保健组织Kupat Holim Meuhedet的首席执行官。从2008年到2013年，他担任Alon Holding Blue Square - Israel Ltd.的首席执行官。在此之前，从2007年到2008年，他担任Phoenix Investments and Finance Ltd.的首席执行官。从2002年到2007年，他是Clalit Health Services Group（以色列最大的医疗保健组织）的首席执行官。他曾担任多个董事会成员，包括2014年至2016年非洲以色列住宅有限公司（TASE： AFRE）， 2006年至2007年贴现银行（TASE：DSCT）， 2005年至2006年U-Bank， 2001年至2006年蓝色广场以色列（TASE： BSI）和Dikla医疗保险有限公司（1995年至2002年）。自2019年以来，他还担任Bar Ilan University的董事会成员。他持有以色列理工学院（Technion, israel Institute of Technology）工业工程和管理学士学位。
- Zeev Vurembrand Zeev Vurembrand has served on board of directors since May 2021. Mr. Vurembrand is currently the Chief Executive Officer and Owner of Vurembrand Management & Innovation Ltd., a position he has held since March 2019, and has been a member of the board of Bezeq the Israeli Telecommunication Corp. Ltd. (TASE: BEZQ) since 2017 and director of Isras Investment Company Ltd. (TASE: ISRAS) since January 2025. Mr. Vurembrand also served as chairman of the board of Lageen Ltd. from 2019 until December 2023. From 2013 until 2019, Mr. Vurembrand was the Chief Executive Officer of Kupat Holim Meuhedet, Israel's third largest health care organization. From 2008 until 2013, he was the Chief Executive Officer of Alon Holding Blue Square – Israel Ltd., and prior to that, from 2007 until 2008, he was the Chief Executive Officer of Phoenix Investments and Finance Ltd. Earlier in his career, from 2002 until 2007, Mr. Vurembrand was the Chief Executive Officer of Clalit Health Services Group, Israel's largest health care organization. Mr. Vurembrand has served on numero boards of directors, including Africa Israel Residences LTD. (TASE: AFRE) from 2014 until 2016, Discount Bank (TASE:DSCT) 2006 until 2007, U Bank from 2005 until 2006, Blue Square Israel (TASE: BSI) from 2001 until 2006, and Dikla Medical Insurance Ltd. from 1995 until 2002. Mr. Vurembrand has also served on the board of trtees of Bar Ilan University since 2019. Mr. Vurembrand holds a B.Sc degree in indtrial engineering and management from the Technion, Israeli Institute of Technology.
- Nir Nimrodi
-
Nir Nimrodi，曾在Odysight.Ai Inc.服役。自2023年8月起担任Ai Inc.的董事。他在生命科学、制药和生物技术行业的初创企业和大型全球企业拥有超过25年的工作经验。从2019年5月到2024年11月，他担任Accellix Inc.（生命科学公司）的董事长兼首席执行官。2014年至2019年4月，他担任Intrexon（现为Precigen， Inc.）的首席商务官。在此之前，他曾担任Life Technologies Inc.（现为Thermo Fisher的一部分）的多个执行职务，并曾担任Proneuron Biotechnologies Inc.和Mindsense Biosystems Ltd.的首席执行官。此外，他目前担任Evogene Ltd.（纳斯达克股票代码：EVGN）和私人公司Genesee Scientific和Scopio Labs的董事会成员。他持有特拉维夫大学（Tel-Aviv University）经济学学士学位和工商管理硕士学位。
Nir Nimrodi Nir Nimrodi has served on board of directors since Augt 2023. Mr. Nimrodi has over 25 years' experience working in start ups and large global binesses in the life sciences, pharmaceutical, and biotechnology indtries. From May 2019 to November 2024, Mr. Nimrodi was the chairman and chief executive officer of Accellix Inc., a life sciences company. From 2014 to April 2019, Mr. Nimrodi was the chief biness officer of Intrexon (currently Precigen, Inc.). Prior to this, he held several executive roles at Life Technologies Inc. (now part of Thermo Fisher), and was chief executive officer at Proneuron Biotechnologies Inc. and Mindsense Biosystems Ltd. In addition, Mr. Nimrodi currently serves as chairman of the board of Evogene Ltd. (NASDAQ: EVGN) and a member of the board of the private companies MNDL Bio and Scopio Labs. From July 2022 to December 2024, Mr. Nimrodi served as a member of the board of Genesee Scientific. Mr. Nimrodi holds a B.A. in Economics and an MBA from Tel Aviv University. - Nir Nimrodi，曾在Odysight.Ai Inc.服役。自2023年8月起担任Ai Inc.的董事。他在生命科学、制药和生物技术行业的初创企业和大型全球企业拥有超过25年的工作经验。从2019年5月到2024年11月，他担任Accellix Inc.（生命科学公司）的董事长兼首席执行官。2014年至2019年4月，他担任Intrexon（现为Precigen， Inc.）的首席商务官。在此之前，他曾担任Life Technologies Inc.（现为Thermo Fisher的一部分）的多个执行职务，并曾担任Proneuron Biotechnologies Inc.和Mindsense Biosystems Ltd.的首席执行官。此外，他目前担任Evogene Ltd.（纳斯达克股票代码：EVGN）和私人公司Genesee Scientific和Scopio Labs的董事会成员。他持有特拉维夫大学（Tel-Aviv University）经济学学士学位和工商管理硕士学位。
- Nir Nimrodi Nir Nimrodi has served on board of directors since Augt 2023. Mr. Nimrodi has over 25 years' experience working in start ups and large global binesses in the life sciences, pharmaceutical, and biotechnology indtries. From May 2019 to November 2024, Mr. Nimrodi was the chairman and chief executive officer of Accellix Inc., a life sciences company. From 2014 to April 2019, Mr. Nimrodi was the chief biness officer of Intrexon (currently Precigen, Inc.). Prior to this, he held several executive roles at Life Technologies Inc. (now part of Thermo Fisher), and was chief executive officer at Proneuron Biotechnologies Inc. and Mindsense Biosystems Ltd. In addition, Mr. Nimrodi currently serves as chairman of the board of Evogene Ltd. (NASDAQ: EVGN) and a member of the board of the private companies MNDL Bio and Scopio Labs. From July 2022 to December 2024, Mr. Nimrodi served as a member of the board of Genesee Scientific. Mr. Nimrodi holds a B.A. in Economics and an MBA from Tel Aviv University.
高管简历
中英对照 | 中文 | 英文- Yehu Ofer
Yehu Ofer，自2022年10月起担任我们的首席执行官。奥费尔曾在以色列空军（简称“IAF”）担任上校（现已退役），在指挥IAF的光学和电子情报部门“Wing 15”之前指挥两个作战中队。奥费尔在担任最后一个职务时，曾担任以色列驻意大利、希腊、塞尔维亚和克罗地亚的国防武官，负责监督以色列和意大利之间有史以来最大规模的政府对政府交易。2013年从以色列国防军退役后，Ofer先生加入了Elbit系统有限公司的电光部门，担任机载光学和激光解决方案的技术开发和项目经理。Ofer先生还管理Elbit System的航空航天部门，担任大型开发项目副总裁和巴西业务部门副总裁。在2022年10月离开Elbit系统成为我们的首席执行官之前，Ofer先生曾担任Elbit系统的全球业务发展、营销和销售副总裁，该职位自2020年起担任。Ofer先生拥有海法大学MBA学位、特拉维夫Bar Ilan大学经济和物流学士学位（优等生）以及特拉维夫国家安全学院学位。Ofer先生自2024年8月起担任Aerospace Industrial Scan Ltd.董事会成员，自2024年9月起担任Robotican Ltd.董事会成员，自2023年11月起担任魏茨曼研究所国际董事会成员。
Yehu Ofer Yehu Ofer has served as Chief Executive Officer since October 2022. Mr. Ofer served as a colonel (now retired) in the Israeli Air Force, or the IAF, commanding two operational squadrons before commanding "Wing 15", the optic and electronic intelligence wing of the IAF. In his last position, Mr. Ofer served as Israel Defense Attaché to Italy, Greece, Serbia, and Croatia, where he oversaw the largest ever government to government transaction beten Israel and Italy. Upon his retirement from the Israel Defense Forces in 2013, Mr. Ofer joined Elbit Systems Ltd. in its electro optics unit as a technology development and program manager in airborne optic and laser solutions. Mr. Ofer also managed Elbit System's aerospace division as VP of large scale development programs and VP of the Brazil biness unit. Before leaving Elbit Systems, in October 2022, to become CEO, Mr. Ofer served as VP of Global Biness Development, Marketing and Sales for Elbit Systems, a position he held since 2020. Mr. Ofer holds an MBA degree from the University of Haifa, a Bachelor of Economics and Logistics degree (cum laude) from Bar Ilan University in Tel Aviv, and a degree from the National Security College in Tel Aviv. Mr. Ofer has served as a member of the board of directors of Aerospace Indtrial Scan Ltd. since Augt 2024, Robotican Ltd since September 2024 and of the International Board of the izmann Institute since November 2023.- Yehu Ofer，自2022年10月起担任我们的首席执行官。奥费尔曾在以色列空军（简称“IAF”）担任上校（现已退役），在指挥IAF的光学和电子情报部门“Wing 15”之前指挥两个作战中队。奥费尔在担任最后一个职务时，曾担任以色列驻意大利、希腊、塞尔维亚和克罗地亚的国防武官，负责监督以色列和意大利之间有史以来最大规模的政府对政府交易。2013年从以色列国防军退役后，Ofer先生加入了Elbit系统有限公司的电光部门，担任机载光学和激光解决方案的技术开发和项目经理。Ofer先生还管理Elbit System的航空航天部门，担任大型开发项目副总裁和巴西业务部门副总裁。在2022年10月离开Elbit系统成为我们的首席执行官之前，Ofer先生曾担任Elbit系统的全球业务发展、营销和销售副总裁，该职位自2020年起担任。Ofer先生拥有海法大学MBA学位、特拉维夫Bar Ilan大学经济和物流学士学位（优等生）以及特拉维夫国家安全学院学位。Ofer先生自2024年8月起担任Aerospace Industrial Scan Ltd.董事会成员，自2024年9月起担任Robotican Ltd.董事会成员，自2023年11月起担任魏茨曼研究所国际董事会成员。
- Yehu Ofer Yehu Ofer has served as Chief Executive Officer since October 2022. Mr. Ofer served as a colonel (now retired) in the Israeli Air Force, or the IAF, commanding two operational squadrons before commanding "Wing 15", the optic and electronic intelligence wing of the IAF. In his last position, Mr. Ofer served as Israel Defense Attaché to Italy, Greece, Serbia, and Croatia, where he oversaw the largest ever government to government transaction beten Israel and Italy. Upon his retirement from the Israel Defense Forces in 2013, Mr. Ofer joined Elbit Systems Ltd. in its electro optics unit as a technology development and program manager in airborne optic and laser solutions. Mr. Ofer also managed Elbit System's aerospace division as VP of large scale development programs and VP of the Brazil biness unit. Before leaving Elbit Systems, in October 2022, to become CEO, Mr. Ofer served as VP of Global Biness Development, Marketing and Sales for Elbit Systems, a position he held since 2020. Mr. Ofer holds an MBA degree from the University of Haifa, a Bachelor of Economics and Logistics degree (cum laude) from Bar Ilan University in Tel Aviv, and a degree from the National Security College in Tel Aviv. Mr. Ofer has served as a member of the board of directors of Aerospace Indtrial Scan Ltd. since Augt 2024, Robotican Ltd since September 2024 and of the International Board of the izmann Institute since November 2023.
- Einav Brenner
Einav Brenner，自2024年5月起担任我们的首席财务官。从2022年5月到成为我们的首席财务官，布伦纳女士担任食品科技公司Solato Ltd.的财务副总裁。布伦纳女士以这一身份支持建立全球公司活动，包括战略决策和重要的商业协议，建立财务和运营团队和基础设施，以及处理资金筹集和投资者关系。2017年7月至2022年5月，Brenner女士在RedHill BioPharma Ltd.（纳斯达克股票代码：RDHL）担任财务执行董事，为筹资活动提供便利，管理复杂的交易和法律方面，并负责证券交易委员会的备案和财务报告。在此之前，布伦纳女士曾在Vizrt Inc.、Viola Ventures和普华永道担任多个财务职位。Brenner女士是注册会计师（以色列），拥有特拉维夫大学会计学、经济学和工商管理学士学位，以及财务管理MBA学位。
Einav Brenner Einav Brenner has served as Chief Financial Officer since May 2024. From May 2022 until becoming CFO, Ms. Brenner served as the VP Finance of Solato Ltd. In this capacity, Ms. Brenner supported the establishment of global company activities, including strategic decision making and significant commercial agreements, building financial and operational teams and infrastructure, and handling fund raising and investor relations. From July 2017 to May 2022, Ms. Brenner served as Executive Director of Finance at RedHill Biopharma Ltd. (NASDAQ: RDHL), where she facilitated fund raising activities, managed complex transactions and legal aspects, and was responsible for SEC filings and financial reporting. Prior to this, Ms. Brenner served in vario financial positions at Vizrt Inc., Viola Ventures and PricewaterhoeCoopers. Ms. Brenner is a CPA (Israel), holds a Bachelor of Accounting, Economics and Biness Administration, and an MBA in Financial Management, both from Tel Aviv University.- Einav Brenner，自2024年5月起担任我们的首席财务官。从2022年5月到成为我们的首席财务官，布伦纳女士担任食品科技公司Solato Ltd.的财务副总裁。布伦纳女士以这一身份支持建立全球公司活动，包括战略决策和重要的商业协议，建立财务和运营团队和基础设施，以及处理资金筹集和投资者关系。2017年7月至2022年5月，Brenner女士在RedHill BioPharma Ltd.（纳斯达克股票代码：RDHL）担任财务执行董事，为筹资活动提供便利，管理复杂的交易和法律方面，并负责证券交易委员会的备案和财务报告。在此之前，布伦纳女士曾在Vizrt Inc.、Viola Ventures和普华永道担任多个财务职位。Brenner女士是注册会计师（以色列），拥有特拉维夫大学会计学、经济学和工商管理学士学位，以及财务管理MBA学位。
- Einav Brenner Einav Brenner has served as Chief Financial Officer since May 2024. From May 2022 until becoming CFO, Ms. Brenner served as the VP Finance of Solato Ltd. In this capacity, Ms. Brenner supported the establishment of global company activities, including strategic decision making and significant commercial agreements, building financial and operational teams and infrastructure, and handling fund raising and investor relations. From July 2017 to May 2022, Ms. Brenner served as Executive Director of Finance at RedHill Biopharma Ltd. (NASDAQ: RDHL), where she facilitated fund raising activities, managed complex transactions and legal aspects, and was responsible for SEC filings and financial reporting. Prior to this, Ms. Brenner served in vario financial positions at Vizrt Inc., Viola Ventures and PricewaterhoeCoopers. Ms. Brenner is a CPA (Israel), holds a Bachelor of Accounting, Economics and Biness Administration, and an MBA in Financial Management, both from Tel Aviv University.
- Eilam Sagi
Eilam Sagi Eilam Sagi自2025年11月起担任首席Biness官。Sagi先生在公共、私营和国防部门拥有30多年的执行、运营、战略和经济经验。在加入公司之前，Sagi先生于2023年10月至2025年10月在Enlight Renewable Energy Ltd.（纳斯达克：ENLT）担任资产管理副总裁，负责全球可再生能源设施每年产生的数亿美元收入。2021年11月至2023年1月，Sagi先生在以色列交通部担任副总经理，与政府和行业利益相关者合作，领导了数十亿美元的基础设施项目、监管改革和国家战略规划。在此之前，Sagi先生从2020年1月起担任Eyeviation的总经理兼董事，Eyeviation是一家专注于神经科学的初创公司，并从2018年12月起担任BINES咨询公司PL S.A.的首席执行官兼董事。在其职业生涯的早期，萨吉曾担任以色列空军预算部部长，获得上校军衔，在那里他与以色列国内外的主要国防承包商一起管理数十亿美元的采购和预算流程。Sagi先生拥有以色列Ramat Gan的Bar Ilan大学经济学和心理学学士学位，以及特拉维夫大学外交和安全研究E.M.B.A.学位。
Eilam Sagi Eilam Sagi has served as Chief Biness Officer since November 2025. Mr. Sagi has more than 30 years of executive, operational, strategic and economic experience across the public, private and defense sectors. Prior to joining the Company, Mr. Sagi served from October 2023 to October 2025 as VP of Asset Management at Enlight Renewable Energy Ltd. (Nasdaq: ENLT), where he was responsible for hundreds of millions of dollars in annual revenues generated by renewable energy facilities worldwide. From November 2021 to January 2023, Mr. Sagi served as Deputy General Manager at the Israeli Ministry of Transportation, where he led multi billion dollar infrastructure programs, regulatory reform and national strategic planning in collaboration with governmental and indtrial stakeholders. Prior to this, Mr. Sagi served from January 2020 as General Manager and Director of Eyeviation, a neuroscience focused startup, and from December 2018 as CEO and Director of Pl S.A., a biness consulting company. Earlier in his career, Mr. Sagi served as Head of the Budget Department for the Israeli Air Force, achieving the rank of colonel, where he managed multi billion dollar procurement and budgeting processes with major defense contractors in Israel and abroad. Mr. Sagi holds a B.A. in Economics and Psychology from Bar Ilan University in Ramat Gan, Israel, and an E.M.B.A. in Diplomacy and Security Studies from Tel Aviv University.- Eilam Sagi Eilam Sagi自2025年11月起担任首席Biness官。Sagi先生在公共、私营和国防部门拥有30多年的执行、运营、战略和经济经验。在加入公司之前，Sagi先生于2023年10月至2025年10月在Enlight Renewable Energy Ltd.（纳斯达克：ENLT）担任资产管理副总裁，负责全球可再生能源设施每年产生的数亿美元收入。2021年11月至2023年1月，Sagi先生在以色列交通部担任副总经理，与政府和行业利益相关者合作，领导了数十亿美元的基础设施项目、监管改革和国家战略规划。在此之前，Sagi先生从2020年1月起担任Eyeviation的总经理兼董事，Eyeviation是一家专注于神经科学的初创公司，并从2018年12月起担任BINES咨询公司PL S.A.的首席执行官兼董事。在其职业生涯的早期，萨吉曾担任以色列空军预算部部长，获得上校军衔，在那里他与以色列国内外的主要国防承包商一起管理数十亿美元的采购和预算流程。Sagi先生拥有以色列Ramat Gan的Bar Ilan大学经济学和心理学学士学位，以及特拉维夫大学外交和安全研究E.M.B.A.学位。
- Eilam Sagi Eilam Sagi has served as Chief Biness Officer since November 2025. Mr. Sagi has more than 30 years of executive, operational, strategic and economic experience across the public, private and defense sectors. Prior to joining the Company, Mr. Sagi served from October 2023 to October 2025 as VP of Asset Management at Enlight Renewable Energy Ltd. (Nasdaq: ENLT), where he was responsible for hundreds of millions of dollars in annual revenues generated by renewable energy facilities worldwide. From November 2021 to January 2023, Mr. Sagi served as Deputy General Manager at the Israeli Ministry of Transportation, where he led multi billion dollar infrastructure programs, regulatory reform and national strategic planning in collaboration with governmental and indtrial stakeholders. Prior to this, Mr. Sagi served from January 2020 as General Manager and Director of Eyeviation, a neuroscience focused startup, and from December 2018 as CEO and Director of Pl S.A., a biness consulting company. Earlier in his career, Mr. Sagi served as Head of the Budget Department for the Israeli Air Force, achieving the rank of colonel, where he managed multi billion dollar procurement and budgeting processes with major defense contractors in Israel and abroad. Mr. Sagi holds a B.A. in Economics and Psychology from Bar Ilan University in Ramat Gan, Israel, and an E.M.B.A. in Diplomacy and Security Studies from Tel Aviv University.